Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Isomorphic Labs, the drug discovery start-up spun out of Google’s DeepMind artificial intelligence unit, has raised $600mn in its first external funding round, as investors bet on the potential for AI ...
Thousands of 3D protein structures locked up in big-pharma vaults will be used to create a new AI tool that won’t be open to ...
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.
The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Isomorphic Labs is raising money in its first-ever external funding round from Thrive Capital, a big backer of ChatGPT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results